News
Article
Author(s):
The new 180,000-square-foot facility in Foster City anchors the company’s long-term $32 billion investment in domestic manufacturing and R&D.
Gilead Sciences has unveiled its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC), nestled in the company’s Foster City, CA headquarters.1
The new 180,000 square-foot plant spans five stories, and represents another accomplished goal in Gilead’s multi-year plan to generate growth and scientific leadership across various sectors, including inflammation, oncology, and virology, with the expansion of biologics services in mind. This concept is part of the company’s intention to invest $32 billion toward domestic manufacturing and R&D through the year 2030.
The financial commitment is anticipated to produce more than $43 billion in economic value for the US.
“This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said Daniel O’Day, Gilead’s chairman and CEO. “We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive US leadership in global biopharma innovation.”
Essentially, the facility is meant to serve as a hub that fosters both collaboration and creativity across the technical development and manufacturing teams. Some of the technology includes autonomous robotics, digitally-enabled systems, and real-time digital monitoring.
This latest investment also creates more than more than 3,000 direct and indirect high-quality jobs in the process.
“California is proud to be home to Gilead Sciences and its ongoing investment in innovation and jobs right here in Foster City,” commented California Lieutenant Governor Eleni Kounalakis. “This new Technical Development Center is more than a milestone for Gilead; it’s a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation.”
This groundbreaking marks a key step in Gilead’s larger expansion at its Foster City HQ. Alongside the NTDC, the company is advancing two additional state-of-the-art projects: a new research building aimed at accelerating scientific discovery, already underway, and a biologics manufacturing facility that is expected to boost US production capacity.
The Gilead commitment to manufacturing also represents an initiative spurred by the various tariffs set forth by President Trump. He has been a proponent of enacting these duties on manufacturers in order to encourage reshoring of these processes back to the United States, which has proven effective, as a plethora of companies are all-in, including Amgen, who will be financially committing upwards of $600 million into a new, state-of-the-art, science and innovation center at its global HQ in Thousand Oaks, CA.2
Ever since the Tax Cuts and Jobs Act (TCJA) of 2017 was passed, Amgen has doubled down on its interest in US innovation, reflected by its over $40 billion invested in manufacturing and research and development, including over $5 billion in direct capital expenditures.
As of now however, tariffs on pharmaceuticals on a grander scale are expected to be forthcoming.
"At Amgen, we're continuing to invest in the future of American science and innovation," said Robert A. Bradway, Amgen’s chairman and CEO. "This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health."
References
1. Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy. Gilead Sciences. September 3, 2025. Accessed September 5, 2025. https://www.gilead.com/news/news-details/2025/gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-u-s--growth-and-innovation-strategy
2. Amgen to Invest $600M in New Science and Innovation Center at California HQ. Pharmaceutical Commerce. September 3, 2025. Accessed September 5, 2025. https://www.pharmaceuticalcommerce.com/view/amgen-to-invest-600m-in-new-science-and-innovation-center-at-california-hq
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
